Skip to main content

Dr. Reddy's Laboratories Ltd ADR(RDY-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low13.42
Day High13.61
Open:13.57
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
FILE PHOTO: Pens for the diabetes drug Ozempic sit on a production line to be packaged at the Danish drugmaker Novo Nordisk's site in Hillerod, Denmark, September 26, 2023. REUTERS/Tom Little/File Photo
the globe and mail

Generic Ozempic to hit pharmacies this week, but availability will vary across Canada

Generic semaglutide from Dr. Reddy’s and Apotex will give Canadians access to the weight-loss drug for a fraction of the cost
Tipranks
Dr. Reddy’s Files Form 6-K and Publishes FY26 Earnings Call Transcript
Tipranks
Dr. Reddy’s Schedules Global Investor Meetings for Late May–Early June 2026
Tipranks
Dr. Reddy’s Launches First Generic Semaglutide Injection in Canada After Health Canada Nod
MarketBeat
Dr. Reddy's Laboratories Q4 Earnings Call Highlights
MarketBeat.com
Tipranks
Dr. Reddy’s Earnings Call: Growth vs. Margin Pain
Tipranks
Dr. Reddy’s Files Q4 FY26 Audited Results Presentation with Exchanges
Tipranks
Dr. Reddy’s Unveils FY 2026 Results, Dividend and Board, Auditor Changes
Tipranks
Dr. Reddy’s posts audio of March-quarter 2026 earnings call for investors
Tipranks
Dr. Reddy’s Revamps Board, Auditors and Senior Leadership in May 12 Governance Push
Tipranks
Dr. Reddy’s Schedules May 2026 Investor Conferences in Mumbai and Singapore
Tipranks
Dr. Reddy’s Grants Over 1.19 Million Employee Stock Options Under ESOP and ADR Schemes
Tipranks
Dr. Reddy’s Board to Weigh Final FY 2025–26 Dividend on April 16 Disclosure
Tipranks
Dr. Reddy’s Divests Svaas Wellness Subsidiary in Small April 2026 Deal
Tipranks
Dr. Reddy’s Allots Equity Shares Under ESOP on March 26, 2026
Tipranks
Dr. Reddy’s Tightens Insider-Information Disclosure Code After Board Approval
Tipranks
Dr. Reddy’s Schedules May 12 Board Meeting to Approve FY 2026 Results, Closes Trading Window
Tipranks
Dr. Reddy’s Launches India’s First DCGI-Approved Generic Semaglutide Obeda for Type 2 Diabetes
Tipranks
Dr. Reddy’s Faces GST Penalty Orders for FY 2019–22, Sees No Material Impact
Tipranks
Dr. Reddy’s Flags Phase III Setback as Immutep Halts Key Lung Cancer Trial

Profile

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.